B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.
Ann Clin Transl Neurol
; 2024 Sep 02.
Article
en En
| MEDLINE
| ID: mdl-39222408
ABSTRACT
This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Ann Clin Transl Neurol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos